Celyad SA (NASDAQ:CYAD) Receives Average Rating of “Strong Buy” from Analysts
Shares of Celyad SA (NASDAQ:CYAD) have earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation. Celyad SA’s rating score has improved by 40.1% in the last three months as a result of various analysts’ ratings changes.
Brokerages have set a 12-month consensus price objective of $40.00 for the company, according to Zacks. Zacks has also assigned Celyad SA an industry rank of 111 out of 265 based on the ratings given to its competitors.
Several analysts have recently weighed in on the stock. ValuEngine upgraded shares of Celyad SA from a “sell” rating to a “hold” rating in a research report on Thursday, June 29th. BidaskClub lowered shares of Celyad SA from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th.
Shares of Celyad SA (NASDAQ:CYAD) traded up 18.57% during trading on Thursday, reaching $37.93. 1,601 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $40.57 and a 200-day moving average price of $32.02. The company’s market capitalization is $361.13 million. Celyad SA has a 52-week low of $16.31 and a 52-week high of $48.93.
An institutional investor recently raised its position in Celyad SA stock. Victory Capital Management Inc. increased its position in Celyad SA (NASDAQ:CYAD) by 6.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 374,493 shares of the company’s stock after buying an additional 22,600 shares during the period. Victory Capital Management Inc. owned approximately 3.93% of Celyad SA worth $9,988,000 as of its most recent SEC filing. Institutional investors own 4.25% of the company’s stock.
Celyad SA Company Profile
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with MarketBeat.com's FREE daily email newsletter.